Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Chemicals Specialty Chemicals
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Figures
View:
Post by fossi_2002 on Feb 14, 2023 5:05am

Figures

After playing the "pipeline" card for a while and apparently not pulling any punches in the market, the stock market is more likely to focus on the Q4 or 2022 figures and the outlook for 2023 in the coming weeks.
Unfortunately, the Q4 numbers are likely to disappoint the market, with Gilles only expecting sales of $3-3.5 mill.
Ceapro is still living off its outstanding 1st and 2nd quarter numbers. Hopefully the full year 2022 trend will continue in the current year.
Comment by Hopeforthebest on Feb 14, 2023 7:54am
Didn't the Golden Phallus hire a revenue officer last year, what's her name, sigrun? What is her job to increase the revenue of the Golden Phallus and his buddies. 2 quarters of reduced revenues great job so far, 2 years of dropping stock prices, many years of failed promises, one primary customer and, yeah, the Golden Phallus is taking this company to the bottom, slowly gradually as he ...more  
Ceapro Inc